1. cannot obtain informed consent. 2. hepatic dysfunction with child pugh score b or c, or alt or ast\> 5 times the upper limit. 3. renal dysfunction with estimated glomerular filtration rate (mdrd) \< 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. bacterial sepsis (besides covid-19 sepsis). 5. known congenital or acquired immune deficiency. 6. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

1. cannot obtain informed consent. 2. hepatic dysfunction with child pugh score b or c, or alt or ast\> 5 times the upper limit. 3. renal dysfunction with estimated glomerular filtration rate (mdrd) \< 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. bacterial sepsis (besides covid-19 sepsis). 5. known congenital or acquired immune deficiency. 6. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

cannot obtain informed consent. hepatic dysfunction with child pugh score b or c, or alt or ast> 5 times the upper limit. renal dysfunction with estimated glomerular filtration rate (mdrd) < 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. bacterial sepsis (besides covid-19 sepsis). known congenital or acquired immune deficiency. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

cannot obtain informed consent. hepatic dysfunction with child pugh score b or c, or alt or ast> 5 times the upper limit. renal dysfunction with estimated glomerular filtration rate (mdrd) < 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. bacterial sepsis (besides covid-19 sepsis). known congenital or acquired immune deficiency. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

1. cannot obtain informed consent. 2. hepatic dysfunction with child pugh score b or c, or alt or ast> 5 times the upper limit. 3. renal dysfunction with estimated glomerular filtration rate (mdrd) < 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. bacterial sepsis (besides covid-19 sepsis). 5. known congenital or acquired immune deficiency. 6. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

1. cannot obtain informed consent. 2. hepatic dysfunction with child pugh score b or c, or alt or ast> 5 times the upper limit. 3. renal dysfunction with estimated glomerular filtration rate (mdrd) < 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. bacterial sepsis (besides covid-19 sepsis). 5. known congenital or acquired immune deficiency. 6. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.